Skip to content
Glipizide
Glucotrol, Metaglip (glipizide) is a small molecule pharmaceutical. Glipizide was first approved as Glucotrol on 1984-05-08. It is used to treat type 2 diabetes mellitus in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Glucotrol (generic drugs available since 1994-05-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glipizide
Tradename
Company
Number
Date
Products
GLUCOTROL XLMylanN-020329 RX1994-04-26
3 products, RLD, RS
Show 1 discontinued
Glipizide
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
METAGLIPBristol Myers SquibbN-021460 DISCN2002-10-21
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
glipizideANDA2023-06-13
glucotrol New Drug Application2021-11-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BB: Sulfonylureas for blood glucose lowering
— A10BB07: Glipizide
HCPCS
No data
Clinical
Clinical Trials
2316 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C2526642381225688
Non-small-cell lung carcinomaD002289391467176250
Pancreatic ductal carcinomaD0214413543101273
Urologic neoplasmsD014571C64-C68112851—36
Renal cell carcinomaD00229241311118
T-cell lymphoma peripheralD016411C84.961012—15
T-cell lymphomaD0163992121—5
Hemophagocytic lymphohistiocytosisD051359D76.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801745711—2205
Breast neoplasmsD001943EFO_0003869C50289432—4146
Urinary bladder neoplasmsD001749C67298424—3125
Lung neoplasmsD008175C34.90228428——122
CholangiocarcinomaD018281C22.1245614—487
Ovarian neoplasmsD010051EFO_0003893C56295217——86
Biliary tract neoplasmsD001661C24.9205612—277
Nasopharyngeal neoplasmsD00930392725—257
SarcomaD01250923373——51
Gallbladder neoplasmsD005706EFO_0004606C23143011—351
Show 66 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151792025——137
Stomach neoplasmsD013274EFO_0003897C16106——215
Kidney neoplasmsD007680EFO_0003865C64211———13
Ovarian epithelial carcinomaD00007721676———12
Esophageal neoplasmsD004938C1554——110
B-cell lymphomaD01639384———9
Endometrial neoplasmsD016889EFO_000423066———9
MelanomaD00854573———8
Multiple myelomaD009101C90.046———7
MesotheliomaD008654C45—7———7
Show 85 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.03————3
Brain neoplasmsD001932EFO_0003833C712————2
Klatskin tumorD018285EFO_10010052————2
Diffuse intrinsic pontine gliomaD0000804432————2
T-cell lymphoma cutaneousD016410C84.A1————1
Rhabdoid tumorD0183351————1
EpendymomaD0048061————1
AstrocytomaD001254EFO_00002711————1
Choroid plexus neoplasmsD016545EFO_00072061————1
OligodendrogliomaD009837EFO_00006311————1
Show 13 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver transplantationD016031EFO_0010682————11
PrognosisD011379————11
InflammationD007249————11
MalnutritionD044342EFO_0008572E40-E46————11
Proton therapyD061766————11
Nasopharyngeal carcinomaD000077274————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGLIPIZIDE
INNglipizide
Description
Glipizide is an N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus. It has a role as a hypoglycemic agent, an EC 2.7.1.33 (pantothenate kinase) inhibitor and an insulin secretagogue. It is a N-sulfonylurea, a member of pyrazines, an aromatic amide and a monocarboxylic acid amide.
Classification
Small molecule
Drug classantidiabetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
Identifiers
PDB—
CAS-ID29094-61-9
RxCUI4821
ChEMBL IDCHEMBL1073
ChEBI ID5384
PubChem CID3478
DrugBankDB01067
UNII IDX7WDT95N5C (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,061 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
43,050 adverse events reported
View more details